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A B S T R A C T
Antibody-drug-conjugates (ADC) are a growing class of anticancer biopharmaceuticals. Conjugation of
cysteine linked ADCs, requires initial reduction of mAb inter-chain disulﬁde bonds, as the drugs are
attached via thiol chemistry. This results in the active mAb moiety being transformed from a covalently
linked tetramer to non-covalently linked complexes, which hinders precise determination of drug load
with LC–MS. Here, we show how the addition of the charge reducing agent triethylammonium acetate
(TEAA) preserves the intact mAb structure, is well suited to the study of cysteine linked conjugates and
facilitates easy drug load determination by direct infusion native MS.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Contents lists available at ScienceDirect
EuPA Open Proteomics
journal homepa ge: www.elsev ier .com/locate /euprot1. Introduction
Antibody-drug-conjugates (ADC) are dynamic and heteroge-
neous mixtures composed of a monoclonal antibody (mAb) linked
via a chemical linker to a biologically active cytotoxic small-
molecule drug. [1–3] The high binding speciﬁcity of mAb and
targeted receptors make ADCs effective delivery systems for
cytotoxic drugs to the tumor cells. In vivo, the ADC is recognized
and binds to the receptor on the surface of the targeted cell.
Subsequently, the ADC is internalized into the cancer cell and
digested in the lysosome, where the cytotoxic drug is released and
consequently kills the target cancer cells, thus reducing systemic
toxicity to the noncancerous cells [4]. Currently, there are two
approved ADC cancer therapies on the market (ADCETRIS for
treatment of relapsed Hodgkin lymphoma and systemic anaplastic
large cell lymphoma, and KADCYLA for treatment of HER2 positive
metastatic breast cancer) with many more in pre-clinical and
clinical development. [5–7]
At present, the dominant conjugation strategies involve
reaction to either lysines or to cysteines. Covalent linking of the
cytotoxic drug to the mAb can be achieved via: (1) reaction of
lysines [8]—attachment to the epsilon amino group of lysine; (2)
reaction of genetically engineered cysteines [9]—attachment to the* Corresponding author.
E-mail address: kamila.pacholarz@manchester.ac.uk (K.J. Pacholarz).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).side chain thiol of unpaired cysteine; or (3) reaction of cysteine
residues generated by the reduction of existing interchain disulﬁde
bonds (DSB) [10,11]. In the latest type of mAb conjugation, the
interchain disulﬁde bridges are partially reduced prior to the
conjugation reaction. The resulting mixture consists of ADCs with
an even number of conjugated drug molecules ranging from zero to
eight. In other words, each disulﬁde cleavage results in the
conjugation of two conjugates. One of the most important
attributes of an ADC is the average number of drug molecules
bound to the mAb, as it determines the amount of drug delivered to
the tumor cells and will inﬂuence its potency [12]. Additionally the
drug distribution proﬁle of the ADC is key for both safety and
efﬁcacy, and needs to be measured accurately and maintained
during manufacturing and formulation including from batch to
batch [13]. Commonly used methods for ADC drug load assessment
and drug-to-antibody ratio (DAR) determination include UV
spectroscopy, capillary electrophoresis (CE), HPLC chromatography
methods such as hydrophobic interaction chromatography (HIC)
and mass spectrometry (MS) [14–18]. According to a recent survey
conducted by Bioanalysis Zone, 82% of those surveyed considered
MS to be a rapid technique of choice for evaluation of the quality
attributes for ADCs at various stages of the development [19].
The dynamic nature and heterogeneity of ADCs raises signiﬁ-
cant bioanalytical challenges. In the case of lysine- or engineered
cysteine-conjugated ADCs, the interchain DSB between heavy and
light chains of a mAb remain intact, and DAR can be determined
using liquid chromatography–mass spectrometry (LC–MS)ics Association (EuPA). This is an open access article under the CC BY-NC-ND license
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[17,20,21]. ADCs conjugated at the interchain cysteine residues
produce a mixture of non-covalent mAb tetramers (2 light chains
(LC) and 2 heavy chains (HC) with a variable number of drug
molecules attached) after reduction of interchain DSBs, hence the
application of more classic LC–MS analytical strategies would
result in dissociation of this non-covalent ADC.
Native MS provides an alternative approach for intact protein
analysis. With appropriate sample preparation, use of aqueous
volatile buffers, and suitable tuningof the instrument, it is possible to
transfer weakly associated complexes from solution into the gas-
phase of a mass spectrometer and obtain insights into complex
stoichiometryand protein structure. Up to date, there have been only
a handful of reports in the literature employing native MS for intact
mass and DAR analysis of these cysteine-linked ADCs [18,22–25]. In
2012, Valliere-Douglass et al. [22] presented the ﬁrst method for the
rapid determination of the mass of an intact ADC intact. In this work,
ADCs were deglycosylated and then subjected to native-SEC
desalting followed by online electrospray MS (ESI-MS) analysis.
They reported some dissociation of the non-covalent ADCs into
conjugated LCs and HCs and reported this having no effect on the
subsequent relative drug load distribution evaluation. A year later,
Chen et al. [18] reported a MS method employing enzymatic
digestion, followed by nano-ESI and native MS to achieve direct
determination of the intact mass and furthermore to calculate the
average DAR of the cysteine-linked ADCs. The cytotoxic conjugates
investigated, often possess high hydrophobicity which will result in
lower proton afﬁnity which may in turn affect the ionisation leading
to an under-representation of high-drug load species. To minimize
this ion suppression and equalise ionisation efﬁciency among
species with different drug loads by reducing the ADC hydrophobic-
ity, limited enzymatic digestion was performed to cleave the
hydrophobic moiety from ADC, while the linker remained attached
and was used as an indicative of the drug load. The DAR values
obtained post-enzymatic digestion were more comparable with
those determined by HIC methods, while DAR values obtained for
samples without enzymatic digestion were slightly lower. In 2014,Fig.1. Mass spectra of 7 mM ADC acquired on the Q-ToF Ultima API US mass spectromete
this parameter results in effective in-source salt clean-up during the desolvation proceDebaene et. al. [24] developed a semi-quantitative method for
determination of average DAR and DAR distribution in cysteine-
linked ADCs based on high resolution MS and ion-mobility MS (IM-
MS) data. The above mentioned [24] along with other [26] studies of
ADCs employed high performance mass spectrometers to generate
excellent results and mass spectra with superior resolution. More
recently, Marcouxetal. reportedonthe use of imidazoleasareducing
agent to resolve overlapping peak distribution of a lysine-conjugated
ADC as an alternative for lower resolution instruments [27]. Native
MS has also been utilized in analysis of changing drug load
distribution in vivo from plasma samples [23].
Here as an alternative, we have explored the use of a charge
reducing agent—triethylammonium acetate (TEAA). By shifting the
m/z distribution to lower values of z (and higher m/z) we minimise
overlapping ADC peaks and also preserve non-covalent interac-
tions. This approach is potentially more feasible for smaller ADC
developers on lower resolution ToF or Q-ToF instruments.
2. Results and discussion
We have investigated several cysteine-linked ADCs using a
nano-ESI-Q-ToF mass spectrometer (Ultima API US, Waters
Corporation). As the mass of the cytotoxic drug and the linker is
relatively small (1 kDa) in comparison to the intact mAb
(150 kDa), to aid the desolvation process and enhance the
resolution for accurate peak assignment and mass determination,
high acceleration voltages (applied to the source sampling cone)
can be applied at the front stages of a mass spectrometer. Often,
use of elevated acceleration voltages leads to dissociation of non-
covalent complexes. Fig. 1, shows mass spectra of 7 mM ADC in
50 mM ammonium acetate acquired at sampling cone voltage of
50 V (a), 100 V (b) and 200 V (c). Use of a lower cone voltage (50–
100), allows preservation of the intact ADC as observed in the m/z
5900–8000 spectral region; however, under such conditions base
line resolution is not achieved. Moreover, under these more gentle
conditions, high levels of residual solvent and salt adducts make
accurate mass determination challenging. Elevating the coner at three different acceleration voltages: 50 V (a),100 V (b) and 200 V (c). Increase of
ss, at the same time leading to dissociation of the non-covalent ADC.
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corresponding to the intact ADC, but also leads to dissociation
of the conjugated LCs, detected in the m/z 1500–2700 spectral
region.
We have found a signiﬁcant improvement in cysteine linked
ADC intact mass analysis with the addition of the charge reducing
agent TEAA which enables preservation of non-covalently bound
mAbs allowing direct DAR evaluation [28]. Addition of certain salts
to the sample buffer has been reported to both reduce the charge of
the ions but also to increase the stability of protein complexes in
the gas phase. [29–32] The charge reducing nature of alkylated
ammonium ions is mainly based on its higher gas-phase basicity
relative to ammonium acetate (the latter is commonly used as a
salt in native MS experiments). The gas-phase basicity of the ionic
species present in the solution controls how much charge is
emitted during the electrospray process. Small ionic electrolytes
with higher gas-phase basicity compete for charges with ionised
sites of the protein and effectively remove the charge from protein
species [33–36]. Moreover, reducing the charge increases the
energy barrier of unfolding and subsequent complex dissociation
[32,37].
We have applied this to several ADCs provided by Piramal
Healthcare [28]. Fig. 2a, shows a mass spectrum of 7 mM ADC inFig. 2. Mass spectra of 7 mM ADC in 100 mM ammonium acetate (a) and in 100 mM am
where the sampling cone voltage is held at 200 V. Addition of TEAA shifts the intact prote
(b) the intact ADC mass region and assignment of ADC species with different drug loa100 mM ammonium acetate buffer acquired at sampling cone
voltage held at 200 V. Peaks corresponding to different forms of the
intact ADC complex are observed in the region m/z 5500–7000.
Additionally a signiﬁcant amount of in source dissociation
products are produced, one light chain + 1 drug molecule frag-
ments (m/z 1800–3500) and two heavy chains + one light chain + n
drug molecules fragments (m/z 7800–11000), making DAR
determination challenging. When TEAA buffer is added to the
sample solution (Fig. 2b), the intact ADC species are now observed
in a higher m/z range (7800–10500), and no dissociation products
are present suggesting the complex is now signiﬁcantly stabilised
against dissociation. Moreover, upon addition of TEAA, the charge
state envelope previously centered at [24+] (Fig. 2a) is now
centered at the [17+] charge state (Fig. 2b). This shift to a lower
average charge state, also helps to resolve overlapping peaks, since
the lower the value of z, the better the separation in a charge state
envelope and as a consequence spectra interpretation and DAR
derivation is rendered more straightforward. The lack of subunit
dissociation upon addition of 10% TEAA to the buffer solution and
application of high acceleration voltage was also observed for other
cysteine-linked ADCs, sample mass spectra are presented in Fig. S1.
The average DAR values for the ADC shown in Fig. 2. have been
calculated in the absence (Fig. 2a) and in the presence of TEAAmonium acetate + 10% TEAA (b) acquired on the Ultima API US mass spectrometer
in peaks to a higher m/z region and preserves non-covalent interactions. (c) Zoom of
d (DL); the average DAR = 3.8  0.1.
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conditions (acceleration voltage of 200 V). The DAR value based on
data acquired in the presence of TEAA was found to be 3.8  0.1;
this value is slightly lower than the solution based value of 4.0  0.1
as determined with HIC-HPLC. This discrepancy is likely due to the
ionisation efﬁciency of the highly conjugated species. Similar to
that reported by Chen et. al. [18], we have found that
physiochemical properties for example the hydrophobicity of
the drug moiety may inﬂuence the ionisation efﬁciency and alter
proton afﬁnity which in turn affects the ionisation leading to an
under-representation of high-drug load species; which provides an
explanation for the discrepancy between MS-based and HIC-HPLC
based DAR value. This deviation could be possibly minimized by
performing enzymatic digestion to remove the drug molecule only
and reduce ionisation suppression of highly-conjugated species.
From the mass spectrum shown in Fig. 2c, we can clearly see that
ADC with 4 drug molecules (DL = 4) is the most abundant, followed
by ADCs with 2 drug molecules (DL = 2), then 6 drug molecules
(DL = 6); and a smaller amount of an ADC with 8 drug molecules
(DL = 8) and unconjugated ADC (DL = 0) (each about 20%). The
average DAR value in the absence of TEAA (Fig. 2a) was calculated
to be 3.5  0.2. Application of high acceleration voltages may cause
the dissociation of non-covalent complexes. In the case of cysteine-
linked ADCs, we have observed dissociation of the light chains
(Fig. 2a, S1a and c). The DAR value here was calculated based on the
peaks corresponding to the intact species only and is signiﬁcantly
lower than the HIC-HPLC-based DAR or even MS-TEAA-based DAR.
The observed dissociation will progressively under-represented
conjugated species as the number of conjugates increases.
Addition of TEAA to the analysis buffer, here ammonium acetate,
preserves intact the entire ADC population even upon application
of a high acceleration voltage resulting in DAR values that are
closer to the solution based DAR (Fig. 2).
3. Conclusions
Superior resolution of large intact molecules with similar
masses can be achieved at lower m/z values using high resolution
instruments, such as modiﬁed Ortibraps [38]. Instrument and
operational costs are signiﬁcantly higher in comparison to
standard Q-ToF instruments. Moreover, such high resolution
instrumentation still often requires custom modiﬁcation in order
to effectively transmit large proteins such as ADCs. Our native mass
spectrometry approach offers a fast, cost effective method for
intact ADC analysis without the use of HPLC solvents. The
application of high acceleration voltages aids the desolvation
process and in-source salt clean up, while addition of TEAA buffer
helps to preserve non-covalent complexes and shifts the charge
state envelope towards higher m/z region. The sample preparation
requires addition of 10% TEAA (by volume) to ADCs contained in
ammonium acetate buffer. Additionally, deglycosylation or pro-
teolytic removal of the drug, as reported by others [18,39,40] could
be performed to enhance the resolution further. We envision this
approach being particularly beneﬁcial to users of lower resolution
MS platforms, as well as with conjugates of low mass.
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